옵션 체인은 다양한 행사가격과 만기일에 대한 Femto Technologies의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Femto Technologies에 대한 시장 심리를 평가합니다..

Femto Technologies (NASDAQ:FMTO) 주식, 옵션 체인

Femto Technologies

Femto Technologies Inc is an integrated software company. It owns and markets Benefit CRM, a proprietary customer relationship management CRM software product enabling small and medium sized businesses to optimize their day to day business activities such as sales management, personnel management, marketing, call center activities, and asset management.

Femto Technologies Inc

NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) affirms FY2025 sales outlook from $8.00 million-$10.00 million to $8.00 million-$10.00 million.

News

Guidance

NMTC

NeuroOne Medical Tech Affirms FY2025 Product Revenue Guidance of $8.00M-$10.00M

Rosenblatt analyst Steve Frankel maintains Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) with a Buy and raises the price target from $24 to $25.

Price Target

Analyst Ratings

LINC

Rosenblatt Maintains Buy on Lincoln Educational Servs, Raises Price Target to $25

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) announced Tuesday morning that its CEO, Andrew Witty, will resign for personal reasons. The change is effective immediately.
Stephen Hemsley, who previously held the CEO title from 2006 to 2017, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45370370/unitedhealth-group-announces-leadership-transition" rel="noreferrer noopener">will succeed him</a>.
Hemsley will also remain chairman of UnitedHealth&#8217;s board of directors, and Witty will become senior adviser to the CEO.
Hemsley joined UnitedHealth Group in 1997 as chief operating officer and became president in 1999. He has been chair of the company&#8217;s board since leaving the CEO role in 2017.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44821140/unitedhealth-demands-rapid-repayment-of-cyberattack-relief-loan-billions-providers-say-push-undermines-recovery" rel="noreferrer noopener">UnitedHealth Demands Rapid Repayment Of Cyberattack Relief Loan Billions, Providers Say Push Undermines Recovery</a>
The company also revealed that it would suspend its 2025 outlook, citing that care activity continued to accelerate.
UnitedHealth noted broadening to more types of benefit offerings than seen in the first quarter, and the medical costs of many Medicare Advantage beneficiaries new to UnitedHealthcare remained higher than expected.
It said it &#8220;expects to return to growth in 2026,&#8221; according to the announcement.
&#8220;UnitedHealth Group has tremendous opportunities to grow as we continue to help improve health care and to perform to our potential — and, in so doing, return to our long-term growth objective of 13 to 16 percent,&#8221; Hemsley continued.
The insurance giant reported adjusted EPS of $7.20 in April, up from $6.91 a year ago, missing the consensus of $7.29. Revenues increased 6.8% year over year to $109.6 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $111.60 billion</a>.
&#8220;UnitedHealth Group…did not perform up to our expectations, and we are aggressively addressing those challenges to position us well for the years ahead and return to our long-term earnings growth rate target of 13 to 16%,&#8221; <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44860240/unitedhealth-slashes-2025-outlook-on-medicare-funding-reductions-stock-crashes" rel="noreferrer noopener">Witty said</a>.
Prior Guidance: UnitedHealth Group cuts its 2025 performance outlook. It expected adjusted earnings of $26.00-$26.50 per share versus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" rel="noreferrer noopener">prior guidance of 29.50-$30.00</a> per share, versus consensus of $29.73, reflecting:
<ul class="wp-block-list">
<li>Heightened care activity indications within UnitedHealthcare&#8217;s Medicare Advantage businesses became visible as the quarter closed, far above the planned 2025 increase consistent with the elevated levels in 2024, most notable within physician and outpatient services.</li>
<li>Unanticipated changes in the profile of Optum Health members are impacting planned 2025 reimbursement due to unexpectedly minimal 2024 beneficiary engagement by plans exiting markets. In addition, a greater-than-expected impact to current and new complex patients from the ongoing Medicare funding reductions enacted by the previous administration.</li>
</ul>
Price Action: At the last check on Tuesday, UNH stock was down 11% at $337.02 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45358050/nano-cap-neurosense-therapeutics-gets-14-price-forecast-as-primec-nears-key-als-milestones" target="_blank" rel="noreferrer noopener">Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Large Cap

Health Care

Management

Movers

General

UnitedHealth Names New CEO, Suspends 2025 Guidance, Stock Plunges

Optex Systems Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPXS#NASDAQ">OPXS</a>) reported quarterly earnings of $0.26 per share. This is a 62.5 percent increase over earnings of $0.16 per share from the same period last year. The company reported $10.73 million in sales this quarter. This is a 25.89 percent increase over sales of $8.52 million the same period last year.

Earnings

OPXS

Optex Systems Hldgs Q2 EPS $0.26 Up From $0.16 YoY, Sales $10.73M Up From $8.52M YoY

HC Wainwright &amp; Co. analyst Kevin Dede maintains Exodus Movement (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#AMEX">EXOD</a>) with a Buy and lowers the price target from $50 to $65.

EXOD

HC Wainwright & Co. Maintains Buy on Exodus Movement, Lowers Price Target to $65

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $10 price target.

CRVO

D. Boral Capital Maintains Buy on CervoMed, Maintains $10 Price Target

Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $(0.21) by 161.9 percent. This is a 146.43 percent increase over losses of $(0.28) per share from the same period last year.

Earnings Beats

CADL

Candel Therapeutics Q1 EPS $0.13 Beats $(0.21) Estimate

Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 17.65 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $130.00 thousand which beat the analyst consensus estimate of $50.00 thousand by 160.00 percent. This is a 12.16 percent decrease over sales of $148.00 thousand the same period last year.

OVID

Ovid Therapeutics Q1 EPS $(0.14), Inline, Sales $130.00K Beat $50.00K Estimate

<h3>Gainers</h3>
<ul>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares increased by 106.6% to $1.57 during Tuesday's pre-market session. The market value of their outstanding shares is at $13.5 million. </li>
<li>Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) shares increased by 59.94% to $11.22. The company's market cap stands at $408.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) stock increased by 12.24% to $23.93. The market value of their outstanding shares is at $756.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) shares moved upwards by 10.37% to $17.55. The company's market cap stands at $668.1 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) shares rose 9.09% to $0.3. The market value of their outstanding shares is at $88.5 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>CarParts.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTS#NASDAQ">PRTS</a>) shares moved upwards by 8.37% to $0.89. The market value of their outstanding shares is at $51.8 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Netclass Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares declined by 13.7% to $25.01 during Tuesday's pre-market session. The company's market cap stands at $445.9 million. </li>
<li>Wah Fu Education Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) shares fell 11.59% to $1.45. The company's market cap stands at $6.4 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock fell 11.13% to $0.93. The market value of their outstanding shares is at $1.6 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares decreased by 9.88% to $2.1. The market value of their outstanding shares is at $9.8 million. </li>
<li>Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares decreased by 7.54% to $1.35. The market value of their outstanding shares is at $4.3 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares fell 7.52% to $0.41. The market value of their outstanding shares is at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTNT

KXIN

LOBO

LSEA

NTCL

PRTS

WAFU

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 90.1% to $2.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 25.15% to $0.19. The market value of their outstanding shares is at $4.7 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 23.11% to $0.9. The market value of their outstanding shares is at $46.5 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares moved upwards by 21.22% to $14.05. The company's market cap stands at $381.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) shares moved upwards by 11.22% to $4.26. The market value of their outstanding shares is at $201.1 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock rose 10.49% to $2.21. The market value of their outstanding shares is at $3.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 91.8% to $0.03 during Tuesday's pre-market session. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock decreased by 36.8% to $0.47. The market value of their outstanding shares is at $106.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 21.63% to $0.11. The company's market cap stands at $2.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares declined by 19.73% to $0.14. The market value of their outstanding shares is at $3.9 million. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) stock fell 16.67% to $0.85. The market value of their outstanding shares is at $98.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 16.59% to $0.35. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCT

AXDX

CHRS

CNSP

ENTO

GCTK

KLTO

PLRZ

RDHL

SGMO

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares rose 54.6% to $5.38 during Tuesday's pre-market session. The company's market cap stands at $3.2 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock rose 48.15% to $0.37. The market value of their outstanding shares is at $7.8 million. </li>
<li>VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares moved upwards by 17.98% to $5.51. The company's market cap stands at $62.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) shares rose 17.96% to $0.89. The company's market cap stands at $18.6 million. </li>
<li>Radiant Logistics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RLGT#AMEX">RLGT</a>) shares increased by 13.89% to $7.05. The company's market cap stands at $331.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares moved upwards by 11.55% to $5.6. The market value of their outstanding shares is at $15.6 million. As per the press release, FY earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) stock declined by 51.1% to $2.41 during Tuesday's pre-market session. The company's market cap stands at $79.9 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) shares decreased by 23.14% to $1.96. The market value of their outstanding shares is at $265.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) shares fell 17.61% to $0.89. The company's market cap stands at $6.6 million. </li>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) shares declined by 16.18% to $6.01. The company's market cap stands at $102.4 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock fell 11.37% to $0.12. The market value of their outstanding shares is at $3.5 million. </li>
<li>Perma-Pipe Inlt Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPIH#NASDAQ">PPIH</a>) stock decreased by 11.24% to $12.01. The company's market cap stands at $95.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTG

GRFX

LICN

MWYN

PPIH

RLGT

VCIG

VSTE

VTSI

WLGS

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares moved upwards by 16.2% to $1.65 during Tuesday's pre-market session. The market value of their outstanding shares is at $114.4 million. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock increased by 13.12% to $2.5. The company's market cap stands at $7.0 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock increased by 10.54% to $3.46. The market value of their outstanding shares is at $34.5 million. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) stock rose 10.44% to $1.48. The company's market cap stands at $18.4 million. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) stock rose 8.13% to $0.32. The company's market cap stands at $4.2 million. </li>
<li>Roadzen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDZN#NASDAQ">RDZN</a>) shares moved upwards by 7.8% to $0.84. The company's market cap stands at $62.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Everspin Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAM#NASDAQ">MRAM</a>) stock decreased by 13.8% to $5.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $115.5 million. </li>
<li>Exodus Movement (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#AMEX">EXOD</a>) shares fell 11.61% to $48.0. The company's market cap stands at $1.3 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares fell 11.39% to $2.34. The company's market cap stands at $458.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares declined by 11.35% to $10.24. The company's market cap stands at $2.9 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares decreased by 10.29% to $3.4. The company's market cap stands at $8.0 million. </li>
<li>Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) stock fell 9.1% to $1.1. The market value of their outstanding shares is at $270.3 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

AMOD

GRYP

INDI

IVDA

MLGO

MRAM

MVIS

RDZN

RGTI

TAOP

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) with a Buy and maintains $10 price target.

Reiteration

FGEN

HC Wainwright & Co. Reiterates Buy on FibroGen, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and lowers the price target from $29 to $17.

IMNN

D. Boral Capital Maintains Buy on Imunon, Lowers Price Target to $17

-Reuters, citing sources familiar

Macro Economic Events

Global

Economics

Trump Envoys Steve Witkoff And Keith Kellogg To Travel To Istanbul For Russia-Ukraine Talks

Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.13) by 453.85 percent. This is a 7.69 percent increase over losses of $(0.78) per share from the same period last year.

Earnings Misses

ARTL

Artelo Biosciences Q1 EPS $(0.72) Misses $(0.13) Estimate

Biotech

SeaStar Medical Reaches Interim Enrollment Target For The NEUTRALIZE-AKI Pivotal Trial Of SCD Therapy In Adult Patients With Acute Kidney Injury

Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year.

ATOS

Atossa Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate

In the preceding three months, 4 analysts have released ratings for Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $2.38, along with a high estimate of $3.00 and a low estimate of $2.00. A decline of 4.8% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747137979_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Microvision. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jesse Sobelson</td>
<td>D. Boral Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Jesse Sobelson</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Microvision. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Microvision compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Microvision's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Microvision's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MVIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Microvision analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Microvision Better</h2>
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
<h3>A Deep Dive into Microvision's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Microvision's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -67.65%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Microvision's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1888.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -54.36%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -29.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Microvision's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.06, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Microvision: 4 Analysts Share Their Views

NRXP

HOPE Therapeutics, Inc. And NRx Pharmaceuticals Sign Agreement To Purchase The Kadima Neuropsychiatry Institute; Deal Subject To Satisfaction Of Standard Closing Conditions And Finalization Of Financing, Further Details On The Transaction Will Be Disclosed At That Time

Press Releases

Power Metallic Mines Inc. (TSX.V: PNPN) Dominates TSX Venture Top 50: #1 Miner, #4 Overall – More Stocks Inside!

Comments

Femto Technologies

Femto Technologies (FMTO) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌